APLLTD - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.4
| Stock Code | APLLTD | Market Cap | 14,971 Cr. | Current Price | 762 ₹ | High / Low | 1,108 ₹ |
| Stock P/E | 21.5 | Book Value | 286 ₹ | Dividend Yield | 1.44 % | ROCE | 12.2 % |
| ROE | 12.9 % | Face Value | 2.00 ₹ | DMA 50 | 746 ₹ | DMA 200 | 805 ₹ |
| Chg in FII Hold | 0.03 % | Chg in DII Hold | 0.00 % | PAT Qtr | 263 Cr. | PAT Prev Qtr | 149 Cr. |
| RSI | 57.8 | MACD | 0.05 | Volume | 2,95,099 | Avg Vol 1Wk | 1,04,711 |
| Low price | 635 ₹ | High price | 1,108 ₹ | PEG Ratio | 0.82 | Debt to equity | 0.21 |
| 52w Index | 26.8 % | Qtr Profit Var | 249 % | EPS | 32.6 ₹ | Industry PE | 32.5 |
📊 APLLTD shows moderate fundamentals for long-term investment. With ROE (12.9%) and ROCE (12.2%), the company demonstrates average capital efficiency. The P/E ratio (21.5) is below the industry average (32.5), suggesting fair valuation. The PEG ratio (0.82) indicates reasonable growth prospects. Dividend yield (1.44%) adds some passive income. Quarterly PAT rose significantly from 149 Cr. to 263 Cr. (+249%), showing strong earnings momentum. Debt-to-equity is low (0.21), ensuring financial stability.
💡 Entry Price Zone: A favorable entry would be between 730 ₹ – 760 ₹, closer to DMA 50 (746 ₹) and DMA 200 (805 ₹), where valuations align better with long-term growth potential.
📈 Exit Strategy / Holding Period: If already holding, consider a 3–5 year horizon given improving profitability and fair valuations. Partial profit booking may be considered near 1,000 ₹ levels if momentum continues. Exit only if earnings growth slows or if ROE/ROCE fail to improve further.
🌟 Positive
- [P/E ratio](ca://s?q=Explain_P/E_ratio) of 21.5 is lower than industry average (32.5), suggesting fair valuation.
- [PEG ratio](ca://s?q=PEG_ratio_explained) of 0.82 indicates reasonable growth prospects.
- Dividend yield of 1.44% provides passive income.
- Quarterly PAT surged from 149 Cr. to 263 Cr., showing strong earnings momentum.
- Low [debt-to-equity](ca://s?q=Debt_to_equity_explained) ratio of 0.21 ensures financial stability.
⚠️ Limitation
- Moderate [ROE](ca://s?q=Explain_ROE) (12.9%) and [ROCE](ca://s?q=Explain_ROCE) (12.2%) indicate average capital efficiency.
- 52-week index at 26.8% shows the stock is trading closer to its lower range, reflecting weak price momentum.
- Institutional activity is muted (FII +0.03%, DII flat).
📰 Company Negative News
- Stock trading near lower end of 52-week range, reflecting weak investor sentiment.
- Capital efficiency metrics remain moderate compared to peers.
📢 Company Positive News
- Quarterly profit growth of 249% highlights strong earnings recovery.
- Dividend yield of 1.44% adds investor appeal.
- Fair valuation compared to industry peers.
🏭 Industry
- Industry P/E at 32.5, higher than company’s 21.5, showing sector-wide premium valuations.
- Pharmaceutical sector growth driven by global healthcare demand and innovation.
✅ Conclusion
APLLTD is a moderately strong candidate for long-term investment with fair valuations, improving profitability, and low debt. Entry is ideal near 730–760 ₹. Long-term investors may hold for 3–5 years, while existing holders can consider partial profit booking near 1,000 ₹ if momentum sustains. Monitoring ROE, ROCE, and quarterly earnings will be crucial for sustained returns.